scientific reports



OPEN Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study

Abraham Ka-chung Wai^{1,2,3,9}, Teddy Tai-loy Lee^{1,9}, Sunny Ching-long Chan¹, Crystal Ying Chan⁴, Edmond Tsz-fung Yip⁵, Luke Yik-fung Luk⁵, Joshua Wing-kei Ho⁵, Kevin Wang-leong So¹, Omar Wai-kiu Tsui¹, Man-lok Lam¹, Shi-yeow Lee¹, Tafu Yamamoto⁶, Chak-kwan Tong⁷, Man-sing Wong⁸, Eliza Lai-yi Wong⁴ & Timothy Hudson Rainer^{1,2}

This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk COVID-19 patients during an Omicron outbreak. Two cohorts, Nirmatrelvir-Ritonavir versus control and Molnupiravir versus control, were constructed with inverse probability treatment weighting to balance baseline characteristics. Cox proportional hazards models evaluated the association of their use with all-cause mortality, respiratory mortality, and all-cause sepsis (a composite of circulatory shock, respiratory failure, acute liver injury, coagulopathy, and acute liver impairment). Patients recruited were hospitalized and diagnosed with the COVID-19 Omicron variant between February 22, 2022 and April 15, 2022, and followed up until May 15, 2022. The study included 17,704 patients. There were 4.67 and 22.7 total mortalities per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio, -18.1 [95% CI - 23.0 to -13.2]; hazard ratio, 0.18 [95% CI, 0.11-0.29]). There were 6.64 and 25.9 total mortalities per 1000 person-days in the Molnupiravir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, -19.3 [95% CI - 22.6 to -15.9]; hazard ratio, 0.23 [95% CI 0.18-0.30]). In all-cause sepsis, there were 13.7 and 35.4 organ dysfunction events per 1000 person-days in the Nirmatrelvir-Ritonavir and control groups respectively before adjustment (weighted incidence rate ratio per 1000 person-days, - 21.7 [95% CI - 26.3 to - 17.1]; hazard ratio, 0.44 [95% CI 0.38-0.52]). There were 23.7 and 40.8 organ dysfunction events in the Molnupiravir and control groups respectively before adjustment (weighted incidence ratio per 1000 person-days, -17.1 [95% CI, -20.6 to -13.6]; hazard ratio, 0.63 [95% CI 0.58–0.69]). Among COVID-19 hospitalized patients, use of either Nirmatrelvir-Ritonavir or Molnupiravir compared with no antiviral use was associated with a significantly lower incidence of 28-days all-cause and respiratory mortality and sepsis.

¹Department of Emergency Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Room 101, 1/F, University of Hong Kong the Hong Kong Jockey Club Building for Interdisciplinary Research, 5 Sassoon Road, Pokfulam, Hong Kong SAR, China. ²Accident and Emergency, Queen Mary Hospital, Hong Kong SAR, China. ³Accident and Emergency, The University of Hong Kong – Shenzhen Hospital, Shenzhen, China. ⁴Centre for Health Systems & Policy Research, JC School of Public Care and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. ⁵Laboratory of Data Discovery for Health, Hong Kong Science and Technology Park, Hong Kong SAR, China. ⁶Accident and Emergency, Yan Chai Hospital, Hong Kong SAR, China. ⁷Department of Medicine and Geriatric, Princess Margaret Hospital, Hong Kong SAR, China. ⁸Department of Land Surveying and Geo-Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China. ⁹These authors contributed equally: Abraham Ka-chung Wai and Teddy Tai-loy Lee. 🗵 email: thrainer @ hku.hk

Abl	breviations

110010100100	
ACE	Angiotensin-converting enzyme
AKI	Acute kidney injury
ASE	Adult sepsis event
CCI	Charlson comorbidity index
CDARS	Clinical data analysis and reporting system
CDC	Centers for disease control and prevention
HA	Hospital authority
HR	Hazard ratio
ICD-9-CM	International classification of diseases, ninth revision, clinical modified
IPTW	Inverse probability treatment weighting
IRD	Incidence rate difference
RdRp	RNA-dependent RNA polymerase
SD	Standard deviation
SDI	Social deprivation index
SMD	Standardized mean difference
VOC	Variant of concern

Since the first outbreak of COVID-19 at the end of 2019, SARS-CoV-2 has led to a pandemic resulting in 530 million confirmed cases and 6.3 million mortalities in the past 30 months¹. Health authorities in different countries attempted to prevent and control the disease by population-wide, non-pharmaceutical interventions, vaccination programs, and the introduction of novel antiviral and immune-modulating agents. Several variants have been identified since then; notably, the Omicron variant of SARS-CoV-2 was declared a variant of concern (VOC) in late November 2021². It is associated with more efficient cell entry, immune evasion, and increased infectivity³.

Patients infected with the Omicron variant may demonstrate a full spectrum of disease⁴. The manifestation of pathology may be found in the respiratory⁵, cardiovascular⁶, hepatic⁴, renal⁷, coagulation⁸ and nervous systems⁹, in addition to mortality. In this connection, these patients are at risk of developing sepsis^{10,11} as defined by Sepsis-3 criteria¹². Viral sepsis is highly prevalent among hospitalized COVID-19 patients, with a reported 77.9% incidence in patients admitted into intensive care units and 33.3% admitted in general wards¹³. Organ dysfunction resulting from sepsis, such as circulatory shock, respiratory failure, acute kidney and liver injuries and coagulopathies may increase risk of death in COVID-19 patients. The early administration of appropriate antivirals in suspected or confirmed respiratory viral infection may stop viral replication, reduce viral load and prevent and manage severe infection¹⁴.

The development of effective oral antivirals against SARS-CoV-2 gives hope to clinicians to manage COVID-19 patients with high risk to sepsis, including neonates and young children, pregnant women, older adults, and immunosuppressed individuals¹⁵, especially when they do not complete COVID-19 vaccination in the community¹⁶. Molnupiravir, an inhibitor of the viral RNA-dependent RNA polymerase (RdRp), and Nirmatrelvir-Ritonavir, an irreversible inhibitor of SARS-CoV-2 main protease (Mpro), are effective against the Omicron variant¹⁷.

After the first isolation of the Omicron variant in Hong Kong in January 2022, the health systems in Hong Kong were overwhelmed during mid-February to mid-April 2022 (5th wave), leading to 1.18 million reported cases and 8,735 mortalities. At the peak of the 5th wave, only 28% of the population received the booster dose¹⁸, which is necessary for substantial protection against the Omicron variant¹⁹, and which is regarded a major contributor to the high mortality. Seventy-one percent (71%) of mortalities were contributed by patients aged 80 years or above, among which 74.5% were unvaccinated and only 0.5% received the booster dose. The oral antivirals have potential to confer protection from developing severe infection to these patients who have not completed their vaccination or booster.

The effectiveness of these antivirals against the Omicron variant to prevent mortality and organ dysfunction among high-risk hospitalized patients is unclear. This study evaluates the association between antivirals (Molnupiravir and Nirmatrelvir-Ritonavir) and all-cause and respiratory mortality and organ dysfunction among high-risk hospitalized COVID-19 patients during an Omicron outbreak.

Methods

Study design and setting. All patients with COVID-19 in Hong Kong were identified through the Clinical Data Analysis and Reporting System (CDARS), which is a territory-wide administrative database managed by the Hospital Authority (HA), the statutory body operating 42 public hospitals and 120 clinics for the population sized 7.4 million in Hong Kong²⁰. This database collects anonymized demographic, clinical and service data, and has been used extensively for large population studies^{21,22}. The Hospital Authority Hong Kong West Cluster/ The University of Hong Kong institutional review board (UW 22-258) approved and waived the requirement for obtaining patient informed consent, and all methods were performed in accordance with relevant guidelines and regulations.

Selection of participants. Patients who fulfilled the following inclusion criteria were included: (1) a diagnosis of COVID-19 under the International Classification of Diseases, Ninth Revision, Clinical Modified (ICD-9-CM); (2) admitted to hospitals under the Hospital Authority during February 22 to April 15, 2022. We defined the index date as the date of admission of an episode coded for COVID-19.

Interventions. Our exposure of interest was Molnupiravir and Nirmatrelvir-Ritonavir among hospitalized COVID-19 patients, with an increased risk of deterioration, including old-age and chronic disease patients. We included hospitalized patients who were aged \geq 60 years; or younger patients aged \geq 18 with at least one chronic disease. Patients with prescription records of Molnupiravir or Nirmatrelvir-Ritonavir within 4 days of hospital admission were allocated into the Molnupiravir and Nirmatrelvir-Ritonavir treatment groups; patients who received both antivirals were excluded from this study. Considering the delayed access to antivirals in early stage of rolling out, patients received Molnupiravir or Nirmatrelvir-Ritonavir later than 4 days from the index date were excluded.

Outcomes. The primary outcomes were 28-days all-cause mortality and respiratory mortality, as detailed in Supplementary Table 1. Secondary outcomes were circulatory shock, respiratory failure, acute kidney injury, coagulopathy, acute liver impairment, and combined organ dysfunction, a composite outcome defined as presence of any one of these other secondary outcomes. Acute organ dysfunction is defined by vasopressor initiation, mechanical ventilation, elevation of lactate, or changes in total bilirubin, platelets or creatinine relative to specified baseline values²³, and the unprecedented prescription of dexamethasone, as directed by the clinical guideline²⁴. We defined these outcomes in reference to a sepsis surveillance toolkit, published by the US Centers for Disease Control and Prevention (CDC), which is a validated approach based on administrative data to facilitate health care facilities to monitor the incidence and outcomes of patients who developed sepsis according to the Sepsis-3 criteria, known as an Adult Sepsis Event (ASE)²⁵. ASE is defined as (1) presumed serious infection, signified by obtained microbiological examination (for example, blood culture) and ≥ 4 consecutive days of antimicrobials (or up until 1 day before mortality, discharge to hospice, transfer to another acute care hospital, or transition to comfort measures) starting within 2 calendar days of when blood cultures were obtained, plus (2) evidence of concurrent organ dysfunction, signified by any of 6 binary indicators of cardiovascular, pulmonary, renal, hepatic, coagulation, or perfusion dysfunction. This approach for the identification of sepsis patients in Hong Kong data from CDARS has been validated, with high sensitivity (0.93), high specificity (0.86) and area under receiver operating characteristic curve $(0.90)^{26}$.

The follow-up of each patient was commenced from the index date, defined as the date of hospital admission, for 28 days or until date of mortality. For secondary outcomes, follow-up time was defined as time from the index date to time of event, or loss of follow up.

Covariates. Baseline data was collected for each patient including sex, age, and socioeconomic status. The socioeconomic status of each patient was determined by the Social Deprivation Index (SDI) of their area of residence²⁷. SDI is derived from six variables to describe the conditions of social deprivation for each residential district: the proportions of the population with unemployment, monthly household income < US\$250, no schooling at all, one-person household, never-married status, and subtenancy. The data comes from population census published by the government. Each of these six variables had significant factor loading for a specific principal factor, and all of them are deemed to be representative indicators of social disadvantage in the published literature and in the setting of the Hong Kong population. SDI for each district was calculated by taking the average of these six selected variables²⁸.

Baseline data was also collected for comorbidities (Charlson Comorbidity Index (CCI), diabetes mellitus, hypertension, stroke, congestive heart failure, atrial fibrillation, schizophrenia, cirrhosis, depression, chronic kidney disease, rheumatoid arthritis, obesity and alcohol abuse) and chronic medication use (antiplatelets and anticoagulants, ACE inhibitors and angiotensin receptor blockers, beta blockers, calcium channel blockers, diuretics, statins systemic corticosteroids, bronchodilators and inhaled corticosteroids, cancer drugs, and rheumatological drugs). The differences in patient characteristics between treatment groups were expressed in terms of standardized mean differences (SMD), where covariates with SMD < 0.2 were considered balanced. The International Classification of Diseases, Ninth Revision (ICD-9) codes used for classification of the comorbidities are available in Supplementary Table 2.

Analysis. Baseline characteristics were expressed as the mean (Standard deviation [SD]) for continuous variables and frequency (%) for categorical variables. Inverse probability treatment weighting (IPTW) based on propensity scores using the aforementioned variables was used to construct a weighted cohort of patients to address potential indication bias due to nonrandomized allocation of patients to the treatment group. IPTW balances baseline characteristics in comparator groups by weighting each patient by the inverse probability of receiving the treatment. Hazard ratios (HR) for the association of Nirmatrelvir-Ritonavir or Molnupiravir use and the study outcomes were estimated over the entire follow-up with weighted Cox proportional hazards regression using weights obtained by IPTW.

Alternatively, given the small event rate, we repeated all analyses utilizing bootstrapping methods followed by sampling with replacement to obtain precise estimates of HRs, incidence rate differences (IRD) and their 95% confidence intervals. Details regarding the bootstrapping method are documented in Supplementary Fig. 1.

Prespecified subgroup analyses were conducted by stratifying the study population by age groups (5-years increments from < 60 to \geq 80), sex, SDI, and presence of diabetes. Further analyses were conducted to investigate the number of mortalities stratified by individual components of organ dysfunction. The number of organ dysfunctions and length of stay were also stratified by survival status at the end of follow-up.

All significance tests were two-tailed and considered significant when the *P* value was less than 0.05. All analyses were conducted using RStudio version 1.4.1717²⁹, using the following packages: *tidymodels* was used to obtain bootstrapped dataframes³⁰, for the subsequent computation of hazard ratios using the *survival* package³¹,

and weighted incidence rate differences via the *fmsb* package^{32,33}. The package 'WeightIt' was used to compute the propensity scores and inverse probability weights³². The package *comorbidity* was used to compute the CCI³⁴.

Ethics approval and consent to participate. This study was approved, and the requirement for obtaining patient informed consent was waived, by the Hospital Authority Hong Kong West Cluster/The University of Hong Kong institutional review board (UW 22-258).

Results

Characteristics of study subjects. From February 22, 2022 to April 15, 2022, 17,925 patients were hospitalized with COVID-19. Of these, 44 patients were excluded for missing demographic data. Nirmatrelvir-Ritonavir was prescribed to 770 patients of whom 105 were excluded either because of the mixed use of antivirals (N=84) or initiating Nirmatrelvir-Ritonavir beyond 4 days after hospital admission (N=21), leaving 665 for further analysis. Of 1784 given Molnupiravir, 156 were excluded due to mixed use of antivirals (N=84) or initiating Molnupiravir beyond 4 days after hospital admission (N=72), leaving 1628 for analysis. These patients with antivirals were weighted against 15,411 patients without antiviral (control) to generate two study cohorts. Supplementary Fig. 2 documents the selection process for the two study cohorts.

Tables 1 and 2 shows patient demographics of patients receiving each antiviral weighted against control, before and after propensity score weighting. Of 665 patients with Nirmatrelvir-Ritonavir use, the mean age was 76.8 (SD, 14) years, 49.9% were men, and 76.1% had a CCI of 0. Among 1,628 with Molnupiravir, the mean age was 80.0 (SD, 13) years, 51.9% were men, and 70.9% had a CCI of 0. In the control group, the mean age was 72.2 years (SD, 25), 54.5% were men, and 71.9% had a CCI of 0.

Before weighting, Nirmatrelvir-ritonavir users had a lower incidence of chronic kidney disease (2.7%) compared to control (8.9%); there was also less use of diuretics in Nirmatrelvir-ritonavir users (11.0%) compared to control (16.8%). Molnupiravir users were more senile, with more patients aged \geq 75 years (70.0%) compared to control (61.8%). Compared to control, molnupiravir users used more medications, including antiplatelets and anticoagulants (37.5% vs. 30.1%), ACE inhibitors and angiotensin receptor blockers (34.0% vs. 27.1%), beta blockers (24.8% vs. 19.4%), calcium channel blockers (45.2% vs. 38.0%), statins (41.2% vs. 33.1%), and antidiabetic medications (24.9% vs. 20.0%). These differences were well addressed through IPTW where all weighted variables had a SMD < 0.01 after IPTW (Tables 1 and 2).

Main results: primary outcomes. Nirmatrelvir-Ritonavir use was significantly associated with a lower risk of all-cause mortality (HR 0.18 [95% CI 0.11–0.29]) and respiratory mortality (Hazard ratio [HR], 0.05 [95% CI 0.02–0.16]) (Fig. 1a). Molnupiravir was similarly significantly associated with a lower risk of all-cause mortality (HR 0.23 [95% CI 0.18–0.30]) and respiratory mortality (HR 0.18 [95% CI 0.12–0.25]) (Fig. 1a).

In subgroup analysis of the Nirmatrelvir-Ritonavir / control cohort, the HRs of all-cause mortality among patients aged 70–74, 75–79, and \geq 80 years were 0.10 (0.01–0.72), 0.12 (0.02–0.87), and 0.21 (0.12–0.36). There were no events among patients aged 60–64 and 65–69 years. The risk decreased with different SDI groups, where the HRs of Q1 (best socioeconomic status), Q2, Q3, and Q4 (worst) were 0.31 (0.13–0.75), 0.20 (0.08–0.48), 0.14 (0.06–0.33), and 0.09 (0.01–0.63) respectively, with a similar pattern for respiratory mortality (Fig. 1b).

In the Molnupiravir/control cohort, the HRs of all-cause mortality among patients aged 60-64, 65-69, 70-74, 75-79, and ≥ 80 years were 0.36 (0.11–1.15), 0.50 (0.20–1.23), 0.31 (0.14–0.70), 0.10 (0.02–0.40), and 0.23 (0.17–0.30). All SDI groups were associated with decreased risks of call-cause mortality, where the HRs of Q1, Q2, Q3, and Q4 were 0.19 (0.09–0.39), 0.26 (0.18–0.39), 0.28 (0.18–0.42), and 0.15 (0.07–0.31) respectively; and respiratory mortality 0.16 (0.06–0.43), 0.19 (0.11–0.34), 0.20 (0.11–0.36) and 0.12 (0.04–0.32) respectively (Fig. 1b).

Secondary outcomes. In the Nirmatrelvir-Ritonavir/control cohort, 1840 patients experienced the composite endpoint of organ dysfunction, including 952 with circulatory shock, 130 with respiratory failure, 300 with coagulopathy, 703 with acute kidney injury (AKI), and 125 with acute liver impairment. There were 13.7 and 35.4 composite events per 1000 person-days (weighted IRD/1000 person-days, -21.7 [95% CI -26.3 to -17.1]) for user vs nonuser. After adjustment, the HR for the composite organ dysfunction outcome was 0.44 (0.38–0.52). Corresponding HRs were 0.45 (0.28–0.71) for circulatory shock and 0.37 (0.31–0.45) for respiratory failure. A statistically significant HR was not observed for AKI (HR 1.00 [95% CI 0.68–1.48]), coagulopathy (HR 1.27 [95% CI 0.74–2.18]), and acute liver impairment (HR, 0.75 [95% CI 0.29–1.92]). (Fig. 1a).

In the Molnupiravir/control cohort, 1979 patients experienced the composite outcome, with a total of 1011 with circulatory shock, 131 with respiratory failure, 319 with coagulopathy, 770 with AKI, and 127 with acute liver impairment. There were 23.7 and 40.8 composite events per 1000 person-days (weighted IRD/1000 person-days, -17.1 [95% CI -20.6 to -13.6]) for user vs nonuser. After adjustment, a statistically significant HR was only observed for the composite outcome (HR 0.63 [95% CI 0.58–0.69]), circulatory shock (HR 0.73 [95% CI 0.58–0.62]), and respiratory failure (HR 0.57 [95% CI 0.52–0.62]). The risk of coagulopathy (HR 1.03 [95% CI 0.71–1.47]), acute liver impairment (HR 0.55 [95% CI 0.26–1.18]), and AKI (HR 1.19 [95% CI 0.96–1.48]) were not significant (Fig. 1a).

Results for all secondary outcomes stratified by sex, age, SDI and diabetes are shown in Figs. 2a,b. The number of mortality in the Nirmatrelvir-Ritonavir, Molnupiravir and control groups, stratified by organ dysfunction are shown in Table 3; The number of organ dysfunctions and length of stay, stratified by survival status are shown in Supplementary Table 3.

	Crude				After inverse probability treatment weighting			
Variable	Nirmatrelvir- ritonavir (n=665)	Control (n = 15,411)	Standardized difference	P value	Nirmatrelvir- ritonavir (n = 665.6)	Control (n = 665.0)	Standardized difference	P value
Age, mean(SD), y	76.83 (14.00)	72.21 (25.30)	0.23	< 0.001	76.83 (14.00)	73.89 (23.17)	0.15	< 0.001
< =65	17.1	22.9	0.20	< 0.001	17.1	17.1	< 0.01	0.925
66–75	22.0	15.3			22.0	22.1		
>75	60.9	61.8			60.9	60.8		
Sex, (%)			0.09	0.593			< 0.01	0.965
Men	49.9	54.5			49.9	49.9		
Women	50.1	45.5			50.1	50.1		
Social Deprivation Index, (%)			0.28	< 0.001			< 0.01	0.999
Q1	19.8	13.2			19.8	20.0		
Q2	29.3	36.5			29.3	29.3		
Q3	39.5	33.2			39.5	39.4		
Q4	11.3	17.1			11.3	11.3		
Comorbidities, (%)	1					n	1	
Charlson comorbidity index			0.10	< 0.001			< 0.01	0.845
0	76.1	71.9			76.1	76.0		
1–2	23.6	27.7			23.6	23.7		
3-4	0.3	0.4			0.3	0.3		
5+	0.0	0.0			0.0	0.0		
Diabetes	6.8	6.6	0.01	0.548	6.8	6.8	< 0.01	0.954
Hypertension	7.7	7.4	0.01	0.097	7.7	7.7	< 0.01	0.906
Stroke	0.9	1.1	0.02	0.043	0.9	0.9	< 0.01	0.910
Congestive heart failure	2.1	2.6	0.03	< 0.001	2.1	2.1	< 0.01	0.879
Atrial fibrillation	2.4	3.3	0.05	0.012	2.4	2.4	< 0.01	0.932
Schizophrenia	0.6	0.4	0.02	0.990	0.6	0.6	< 0.01	0.980
Liver cirrhosis	0.9	0.2	0.09	0.412	0.9	1.0	< 0.01	0.659
Depression	0.3	0.2	0.01	0.861	0.3	0.3	< 0.01	0.954
Chronic kidney disease	2.7	8.9	0.27	< 0.001	2.7	2.7	< 0.01	0.961
Rheumatoid arthritis	0.3	0.4	0.01	1.000	0.3	0.3	< 0.01	0.879
Obesity	1.1	0.5	0.06	0.861	1.1	1.1	< 0.01	0.797
Alcohol abuse	0.0	0.1	0.05	1.000	0.0	0.0	< 0.01	0.857
Medication use, (%)								
Antiplatelets and anticoagulants	24.4	30.1	0.13	< 0.001	24.4	24.3	< 0.01	0.777
ACE inhibitors and Angiotensin receptor blockers	27.8	27.1	0.02	< 0.001	27.8	27.9	< 0.01	0.652
Beta blockers	17.9	19.4	0.04	< 0.001	17.9	17.8	< 0.01	0.803
Calcium channel blockers	37.1	38.0	0.02	< 0.001	37.1	37.2	< 0.01	0.723
Diuretics	11.0	16.8	0.17	< 0.001	11.0	10.9	< 0.01	0.877
Statins	31.4	33.1	0.04	< 0.001	31.4	31.5	< 0.01	0.679
Systemic corticosteroids	3.3	5.2	0.10	< 0.001	3.3	3.3	< 0.01	0.877
Antidiabetics	20.5	20.0	0.01	< 0.001	20.5	20.5	< 0.01	0.657
Bronchodilators and Inhaled corticosteroids	0.6	0.8	0.02	0.033	0.6	0.6	< 0.01	0.997
Cancer drugs	0.3	0.2	0.01	0.548	0.3	0.3	< 0.01	0.962
Rheumatological drugs	5.1	7.5	0.10	< 0.001	5.1	5.1	< 0.01	0.879

Table 1. Demographics of 16,076 Hospitalized COVID-19 Patients, Before and After Inverse ProbabilityTreatment Weighting.

	Crude				After inverse probability treatment weighting				
Variable	Molnupiravir (n = 1628)	Control (n = 15,411)	Standardized difference	P value	Molnupiravir (n=1628.0)	Control (n = 1628.6)	Standardized difference	P value	
Age, mean(SD), y	80.01 (13.21)	72.21 (25.30)	0.39	< 0.001	80.01 (13.21)	77.52 (20.04)	0.15	< 0.001	
< = 65	12.5	22.9	0.28	< 0.001	12.5	12.5	< 0.01	0.999	
64-75	17.5	15.3			17.5	17.5			
≥75	70.0	61.8			70.0	70.0			
Sex, (%)			0.05	0.252			< 0.01	0.974	
Men	51.9	54.5			51.9	51.9			
Women	48.1	45.5			48.1	48.1			
Social Deprivation Index, No. (%)			0.12	< 0.001			< 0.01	1.000	
Q1	17.4	13.2			17.4	17.3			
Q2	34.8	36.5			34.8	34.9			
Q3	32.2	33.2			32.2	32.2			
Q4	15.6	17.1			15.6	15.6			
Comorbidities, (%)	1	I	L		1	I	1		
Charlson Comorbidity Index			0.03	0.274			< 0.01	0.993	
0	70.9	71.9			70.9	71.0			
1-2	28.7	27.7			28.7	28.8			
3-4	0.4	0.4			0.4	0.4			
5+	0.0	0.0			0.0	0.0			
Diabetes	7.4	6.6	0.03	0.089	7.4	7.4	< 0.01	0.938	
Hypertension	9.7	7.4	0.08	< 0.001	9.7	9.8	< 0.01	0.939	
Stroke	0.7	1.1	0.04	0.283	0.7	0.7	< 0.01	0.994	
Congestive heart failure	2.0	2.6	0.04	0.047	2.0	2.1	< 0.01	0.992	
Atrial fibrillation	3.1	3.3	0.01	0.554	3.1	3.1	< 0.01	0.995	
Schizophrenia	0.6	0.4	0.02	0.204	0.6	0.6	< 0.01	0.897	
Liver cirrhosis	0.1	0.2	0.04	1.000	0.1	0.1	< 0.01	0.980	
Depression	0.3	0.2	0.01	0.879	0.3	0.3	< 0.01	0.977	
Chronic kidney disease	10.7	8.9	0.06	< 0.001	10.7	10.7	< 0.01	0.893	
Rheumatoid arthritis	9.5	0.4	0.01	0.265	0.4	0.4	< 0.01	0.973	
Obesity	0.5	0.5	< 0.01	1.000	0.5	0.5	< 0.01	0.909	
Alcohol abuse	0.1	0.1	0.02	1.000	0.1	0.1	< 0.01	0.931	
Medication use, (%)									
Antiplatelets and anticoagulants	37.5	30.1	0.16	0.117	37.5	37.6	< 0.01	0.914	
ACE inhibitors and Angiotensin receptor blockers	34.0	27.1	0.15	0.108	34.0	34.0	< 0.01	0.895	
Beta blockers	24.8	19.4	0.13	0.117	24.8	24.8	< 0.01	0.914	
Calcium channel blockers	45.2	38.0	0.15	0.836	45.2	45.2	< 0.01	0.914	
Diuretics	20.2	16.8	0.09	0.656	20.2	20.2	< 0.01	0.981	
Statins	41.2	33.1	0.17	0.099	41.2	41.3	< 0.01	0.908	
Systemic corticosteroids	6.6	5.2	0.06	0.519	6.6	6.6	< 0.01	0.893	
Antidiabetics	24.9	20.0	0.12	0.240	24.9	25.0	< 0.01	0.893	
Bronchodilators and Inhaled corticosteroids	9.5	0.8	0.06	0.019	0.3	0.3	< 0.01	0.992	
Cancer drugs	0.6	0.2	0.05	0.103	0.6	0.6	< 0.01	0.884	
Rheumatological drugs	9.5	7.5	0.07	0.461	9.5	9.4	< 0.01	0.948	

Table 2. Demographics of 17,039 Hospitalized COVID-19 Patients, Before and After Inverse ProbabilityTreatment Weighting. ACE Angiotensin converting enzyme.

Limitations

Hong Kong has a robust and comprehensive database from which we acquired real-world clinical data for analysis. However, patients' symptomatology, SARS-CoV-2 vaccination status and vital sign measurements throughout the health care process were not available. Moreover, medical compliance data was not available, and therefore fidelity for these confounders cannot be adjusted.

With the recent availability of these antivirals and the proximity to the outbreak, this study has short follow-up, meaning that late outcomes/effects, for example, prevention of long-term consequences of infection or associated health service utilization, are not assessable during the study period.

Discussion

This analysis from the real-life data among patients infected with the Omicron variant in Hong Kong investigated the association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis. In this study, both antivirals were associated with large degrees of reduction in all-cause and respiratory mortalities, which is compatible with published literature^{11,35-37}, indicating its potential contribution to contain the infection from the epidemic.

Sepsis is a clinical syndrome that has physiologic and biochemical abnormalities caused by a dysregulated host response to infection. Sepsis and the inflammatory response that ensues can lead to multiple organ dysfunction syndrome and death¹². In a viral infection neither blood nor lower respiratory tract specimen culture are positive. In COVID-19, the proportion of viral sepsis among all-cause sepsis was reported as 76%³⁸. In this study, both Nirmatrelvir-Ritonavir and Molnupiravir were associated with a reduction in organ dysfunction driven by a decrease in circulatory shock and respiratory failure among high-risk hospitalized patients infected with Omicron variant.

SARS-CoV-2 was detected in the highly-vascularized heart, respiratory tract, kidneys, liver, and brain³⁹. Endothelial cells express the angiotensin-converting enzyme 2 (ACE2) receptor and the cellular proteases, which are favorable to SARS-CoV-2 and subsequent virus dissemination to various organs through vasculature. A very high level of cytokine facilitates the development of cytokine storm in COVID-19⁴⁰.

Influenza viruses, including influenza A and B, can cause both seasonal epidemics and out-of-season sporadic cases and outbreaks⁴¹. A previous report from the USA found that the incidence rate of influenza-associated sepsis hospitalization was 8.8/100,000 person-years (95% CI 3.9–16.5)⁴². The relative risk of sepsis and septic shock in 2009 pandemic influenza A was 1.70 (95% CI 1.46–1.97) over seasonal influenza⁴³. A report from Wuhan suggesting that COVID-19 (wild-type) associated sepsis and septic shock can be found in 59% and 20% of patients respectively. However, at the time of writing, the data on Omicron variant-associated sepsis and septic shock was not available. In this study, the incidence of sepsis and septic shock among hospitalized patients with Omicron variant was 42.8% (N=7593) and 5.8% (N=1029) respectively. Even though the figure is lower than wild-type, an infection with Omicron may pose a huge burden to health care systems due to its highly transmissible nature.

In this study, the effect of Nirmatrelvir-Ritonavir and Molnupiravir on acute kidney injury, acute liver impairment and coagulopathy were not significant. We reproduced the results with bootstrapping methods to obtain precise estimates of incidence rate ratios, hazard ratios and confidence intervals. After bootstrapping, the antivirals were significantly additionally associated with reduced acute liver impairment, suggesting its potential effect on liver or kidney dysfunctions.

The effectiveness and utility of Nirmatrelvir-Ritonavir and Molnupiravir have been evaluated in other observational studies^{44–47}. One Italian study similarly found decreased risk of death and hospitalization associated with COVID-19 antiviral use⁴⁴. In a study of hospitalized patients without need of supplemental oxygen, use of Nirmatrelvir-Ritonavir (HR: 0.34 [95% CI 0.23–0.50]) and Molnupiravir (HR 0.48 [95% CI 0.40–0.59]) decreased all-cause mortality⁴⁵. In another study conducted on non-hospitalized, community-dwelling patients, Nirmatrelvir-Ritonavir decreased risk of hospitalization (HR 0.76 [95% CI 0.67–0.86]) but not Molnupiravir (HR 0.98 [95% CI 0.89–1.06])⁴⁶. In terms of cost-effectiveness, both Nirmatrelvir-Ritonavir and Molnupiravir were associated with healthcare system cost savings⁴⁷.

These findings should be interpreted together with vaccination status in the population. In Hong Kong, these antivirals were prescribed for individuals who have not completed vaccination against COVID-19 (either attenuated virus vaccine or messenger Ribonucleic Acid vaccine). The elderly population is largely unvaccinated and more likely to develop severe COVID-19. As of April 15, 2022, only 40.0% of population aged 60 years or above have completed vaccination (3 doses), of which 60 to 69 years 50.0%, 70–79 years 38.4% and 80 years or above 14.9%⁴⁸. These observations warrant further analysis, including the number of vaccine doses, to explore the underlying factors accounting for differences in antiviral efficacy among different age groups.

In subgroup analysis, it was found that antivirals had no significant reduction in outcomes among patients aged 60 or under, in contrary to patients from other age groups. While further analysis is warranted for the underlying cause, these patients have additional risk factors for severe disease, suggesting comorbidities and disease factors, rather than age, contribute more to all-cause sepsis.

In summary, this analysis of real-world application of oral antivirals to patients infected with Omicron variant demonstrated that both Molnupiravir and Nirmatrelvir-Ritonavir were associated with a reduction in all-cause and respiratory mortality, and sepsis. Further research, including from randomized clinical trials, is needed to

Outcomes	Weighted rate		Walahtad IDD/1000 area	on-days					
	Nitrmatrelvir-	ritonavir Contr	ol Weighted IRD/1000 pers- (95% C.I.)	on-days HR (95% C.I)					
Primary Outcomes									
All-Cause Mortality	4.67 0.876	22.7 14.1	-18.10 (-23.00 to -13.20) -13.20 (-16.70 to -9.65)	0.18 (0.11 to 0.29) 0.05 (0.02 to 0.16)					
Respiratory Mortality Secondary Outcomes	0.070	14.1	-13.20 (-16.70 to -9.65)	0.05 (0.02 10 0.16)	-				
Circulatory Shock	1.32	2.97	-1.66 (-2.77 to -0.55)	0.45 (0.28 to 0.71)	-		-		
Respiratory Failure	9.82	30.4	-20.60 (-24.60 to -16.50)	0.37 (0.31 to 0.45)		•	1		
Acute Kidney Injury	1.97	1.96	0.01 (-1.04 to 1.06) 0.21 (-0.50 to 0.93)	1.00 (0.68 to 1.48) 1.27 (0.74 to 2.18)			-	-	
Coagulopathy Acute Liver Impairmen		0.802	-0.12 (-0.60 to 0.36)	0.75 (0.74 to 2.18)	_			-	
Composite	13.7	35.4	-21.70 (-26.30 to -17.10)	0.44 (0.38 to 0.52)			-		
					0.0		1.0		
							HR (95% C.I)		
	Weighted rate/10	00 person-days							
Outcomes	Molnupiravir	Control (9	ighted IRD/1000 person-days 5% C.I.)	HR (95% C.I.)					
Primary Outcomes							1		
All-Cause Mortality	6.64		1.30 (-22.60 to -15.90)		•				
Respiratory Mortality	3.21	16.3 -13	I.10 (-15.60 to -10.50)	0.18 (0.12 to 0.25)	-		1		
Secondary Outcomes Circulatory Shock	2.34	3.22 -0.	88 (-1.69 to -0.07)	0.73 (0.58 to 0.92)		-	_		
Respiratory Failure	18.1		i.80 (-19.90 to -13.80)	0.57 (0.52 to 0.62)					
Acute Kidney Injury	2.84		6 (-0.32 to 1.24)	1.19 (0.96 to 1.48)					
Coagulopathy	0.979		2 (+0.45 to 0.49)	1.02 (0.71 to 1.47)		_	-	_	
Acute Liver Impairmen	nt 0.205 23.7		17 (-0.42 to 0.09) .10 (-20.60 to -13.60)	0.55 (0.26 to 1.18) 0.63 (0.58 to 0.69)					
Composite	23.7	40.8 -1	.10 (+20.60 to +13.60)	0.63 (0.58 to 0.69)		-	10		2
(b)				0.0		н	1.0 R (95% C.I)		2
(6)									
		ts / No. at risk	Weighted IRD/ 1000 per	on-days					
Outcomes	Nirmatrelvir-riton	avir Control	(95% C.I.)	HR (95% C.L)					
All-Cause Mortality						1			
Sex					_	1			
	6 / 333 10 / 332	1124 / 701 1492 / 835		0.14 (0.06 to 0.32) 0.21 (0.11 to 0.39)					
Men Age group	10/332	14927839	8 -17.60 (-24.80 to -10.40)	0.21 (0.11 to 0.39)	-				
	1/65	90 / 2812	-3.16 (-13.90 to 7.54)	0.53 (0.08 to 3.51)	-	-			
60 - 64	0 / 49	73 / 723	-14.40 (-34.70 to 5.82)	0.00 (0.00 to 0.00)	•				
	0 / 48	114 / 1019	-14.80 (-26.00 to -3.60)	0.00 (0.00 to 0.00)					
	1/98 1/68	173 / 1338 232 / 1487		0.10 (0.01 to 0.72)	-				
	1 / 68 13 / 337	232 / 1487 1934 / 803	-15.80 (-29.00 to -2.62) 2 -22.50 (-30.30 to -14.80)	0.12 (0.02 to 0.87) 0.21 (0.12 to 0.36)					
SDI	101 001	100411000	E E2.00 (00.00 10 14.00)	0.21 (0.12 (0.00)	-				
Q1	5 / 132	285 / 2029	-17.30 (-26.20 to -8.30)	0.31 (0.13 to 0.75)	-				
	5 / 195	987 / 5624	-19.30 (-27.00 to -11.70)	0.20 (0.08 to 0.48)	-				
	5/263	819/5121		0.14 (0.06 to 0.33)	-				
Q4 Diabetes	1/75	525 / 2637	-13.10 (-23.80 to -2.30)	0.09 (0.01 to 0.63)	-				
	16 / 620	2426 / 143	90 -18.10 (-23.30 to -12.90)	0.19 (0.12 to 0.31)					
	0 / 45	190 / 1021	-17.50 (-30.70 to -4.34)	0.00 (0.00 to 0.00)					
Respiratory Mortality						1			
Sex Women	1/333	696 / 7013	-12.90 (-17.80 to -7.99)	0.04 (0.01 to 0.26)					
	2/332	935 / 8398	-12.90 (-17.80 to -7.99) -13.50 (-18.70 to -8.36)	0.04 (0.01 to 0.26) 0.06 (0.02 to 0.26)					
Age group				(
	0 / 65	47 / 2812	-3.45 (-9.37 to 2.47)	0.00 (0.00 to 0.00)					
	0/49	41 / 723	-8.41 (-23.90 to 7.05)	0.00 (0.00 to 0.00)					
	0 / 48 0 / 98	62 / 1019 101 / 1338	-7.43 (-15.40 to 0.50) -9.76 (-17.40 to -2.11)	0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00)					
	1/68	128 / 1487		0.23 (0.03 to 1.62)		-	_		
>= 80	2/337	1252 / 803	2 -18.00 (-23.60 to -12.40)	0.05 (0.01 to 0.19)					
SDI									
	1/132	161 / 2025 595 / 5624	-12.50 (-18.80 to -6.12)	0.11 (0.02 to 0.75)	1				
	1 / 195 1 / 263	595 / 5624	-14.00 (-19.80 to -8.28) -18.80 (-30.90 to -6.67)	0.06 (0.01 to 0.44) 0.04 (0.01 to 0.29)	-				
	0 / 75	343 / 2637		0.00 (0.00 to 0.00)					
Diabetes						1			
	3 / 620	1509 / 143		0.05 (0.02 to 0.17)					
Yes	0 / 45	122 / 1021	-11.30 (-21.80 to -0.70)	0.00 (0.00 to 0.00)		10	2	20	
					0.0	1.0	2.0	3.0	
	No. of Events /	No. at risk							
		w N	leighted IRD/ 1000 person-day	B HR (95% C.I.)					
- Dutcomes		(5	5% C.I.)			_			
All-Cause Mortality									
All-Cause Mortality Sex Women	36 / 783 1'		7.30 (-22.10 to -12.50)	0.28 (0.20 to 0.40)					
All-Cause Mortality Sex Women : Men :	36 / 783 1'	124 / 7013 -1	7.30 (-22.10 to -12.50) 1.20 (-25.80 to -16.50)	0.28 (0.20 to 0.40)					
All-Cause Mortality Sex Women : Men : Age group	36 / 783 1* 28 / 845 14	124 / 7013 -1 192 / 8398 -2	1.20 (-25.80 to -16.50)	0.19 (0.13 to 0.28)					
All-Cause Mortality Sex Women : Men : Age group < 60	36 / 783 1' 28 / 845 14 1 / 115 90	124 / 7013 -1 192 / 8398 -2 0 / 2812 -6	1.20 (-25.80 to -16.50)	0.19 (0.13 to 0.28)					
All-Cause Mortality Sex Women : Men : Age group < 60 60 - 64 :	36 / 783 1* 28 / 845 1+ 1 / 115 90 3 / 89 7:	124 / 7013 -1 192 / 8398 -4 0 / 2812 -6 8 / 723 -5	1.20 (-25.80 to -16.50)	0.19 (0.13 to 0.28)					
All-Cause Mortality Sex Women : Men : Age group < 60 60 - 64 : 65 - 69	36 / 783 1* 28 / 845 1+ 1 / 115 9i 3 / 89 7: 5 / 108 1*	124 / 7013 -1 192 / 8398 -4 0 / 2812 -6 8 / 723 -6 14 / 1019 -7	1.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .29 (-25.10 to 6.55)	0.19 (0.13 to 0.28)					
All-Cause Mortality Sex Women Men Age group < 60	36 / 783 1' 28 / 845 14 1 / 115 9(3 / 89 7' 5 / 108 1' 6 / 177 1' 2 / 171 2'	124 / 7013 -1 192 / 8398 -2 0 / 2812 -6 8 / 723 -5 14 / 1019 -1 73 / 1338 -1 32 / 1487 -1	11.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .29 (-25.10 to 6.55) .00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26) 6.60 (-24.20 to -8.89)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70) 0.10 (0.02 to 0.40)					
All-Cause Mortality Sex Women : Age group € 60	36 / 783 1' 28 / 845 1 4 1 / 115 9(3 / 89 7' 5 / 108 1' 6 / 177 1' 2 / 171 2'	124 / 7013 -1 192 / 8398 -2 0 / 2812 -6 8 / 723 -5 14 / 1019 -1 73 / 1338 -1 32 / 1487 -1	1.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .29 (-25.10 to 6.55) .00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70)					
All-Cause Mortality Sex Women : Age group < 60 60 - 64 55 - 69 70 - 74 75 - 80 >= 80 SDI	36 / 783 1* 28 / 845 1+ 1 / 115 99 3 / 89 7* 5 / 108 1* 6 / 177 1* 2 / 171 2* 47 / 968 11	124 / 7013 -1 1992 / 8398 -2 0 / 2812 -6 8 / 723 -5 14 / 1019 -1 37 / 1338 -1 32 / 1487 -1 334 / 8032 -2	11.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .28 (-25.10 to 6.55) :00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26) 6.60 (-24.20 to -8.89) 4.20 (-28.80 to -19.50)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70) 0.10 (0.02 to 0.40) 0.23 (0.17 to 0.30)		_			
All-Cause Mortality Sex Women 1 Men 2 Age group 4 60 60 6 60 64 1 75 – 80 2 2 >>800 60 60 Q1 21 21	36 / 783 1* 28 / 845 1+ 1 / 115 90 3 / 89 7; 5 / 108 1* 6 / 177 1; 2 / 171 2; 2 / 171 2; 8 / 283 22	124 / 7013 -1 192 / 8398 -2 0 / 2812 -6 8 / 723 -5 14 / 1019 -1 73 / 1338 -1 32 / 1487 -1 334 / 8032 -2 35 / 2029 -1	11.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .29 (-25.10 to 6.55) .00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26) 6.60 (-24.20 to -8.89)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70) 0.23 (0.17 to 0.30) 0.19 (0.09 to 0.39)					
All-Cause Mortality Sex Women 3 Age group 4 60 - 64 6 60 - 64 7 70 - 74 6 70 - 74 6 70 - 80 2 80 8 OL 4 Q1 Q2	36 / 783 1 ' 28 / 845 1 4 1 / 115 90 3 / 89 72 5 / 108 1 1 6 / 177 1 1 6 / 177 1 1 2 / 171 22 4 7 / 968 1 1 8 / 283 22 27 / 567 90	124 / 7013 -1 192 / 8398 -2) / 2812 -6 3 / 723 -5 14 / 1019 -1 32 / 1487 -1 334 / 8032 -2 35 / 2029 -1 37 / 5624 -1	11.20 (-25.80 to -16.50) .42 (-14.00 to 1.19) .29 (-25.10 to 6.55) .00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26) .60 (-24.20 to -8.89) 4.20 (-28.90 to -19.50) 8.50 (-24.00 to -13.00)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70) 0.23 (0.17 to 0.30) 0.19 (0.09 to 0.39)					
All-Cause Mortality Sex Women : Age group < 60 - 64 0 : 65 - 69 0 : 576 - 80 0 : >≈ 80 0 : 01 0 : 02 0 : 03 0 : 04 :	36 / 783 1* 28 / 845 1+ 1 / 115 9(3 / 89 7; 5 / 108 1* 6 / 177 1*; 2 / 171 22; 4 7 / 968 11 8 / 283 22 27 / 567 9(22 / 524 8*	124 / 7013 -1 102 / 8398 -2 0 / 2812 -6 3 / 723 -5 14 / 1019 -1 37 / 1338 -1 32 / 1487 -1 334 / 8032 -2 355 / 2029 -1 37 / 5624 -1 19 / 5121 -2	11.20 (-25.80 to -16.50) 42 (-14.00 to 1.19) 22 (-25.10 to 6.55) .00 (-18.00 to 4.03) 1.30 (-20.30 to -2.26) 6.60 (-24.20 to -8.89) 4.20 (-28.90 to -19.50) 8.50 (-24.00 to -13.00) 7.00 (-22.90 to -11.00)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.31 (0.14 to 0.70) 0.10 (0.02 to 0.40) 0.23 (0.17 to 0.30) 0.19 (0.09 to 0.39) 0.56 (0.18 to 0.39)	-				
All-Cause Mortality Sex Women : Age group 60 – 64 : 60 – 64 : 75 – 60 : >= 80 75 – 80 : 50 01 : 02 : 03 : 04 : :	38 / 783 11 28 / 845 14 1 / 115 94 5 / 108 17 5 / 108 17 6 / 177 11 8 / 283 22 27 / 567 94 22 / 524 8 7 / 254 52	124 / 7013 -1 192 / 8398 -3 3 / 2812 -4 3 / 723 -4 14 / 1019 -1 73 / 1338 -1 12 / 1487 -1 3 / 1338 -2 22 / 1487 -1 3 / 334 / 8032 -2 35 / 2029 -1 55 / 2029 -1 57 / 5524 -1 19 / 5121 -2 55 / 2637 -1	1:20 (-25:80 to -16:50) 4:2 (-14:00 to 1.19) 20 (-25:10 to 6.35) (-18:00 to 4.33) 1:30 (-2030 to -2.28) 6:00 (-24:20 to -4.39) 4:20 (-28:90 to -19:50) 5:80 (-24:00 to -13:00) 7:00 (-22:80 to -11:00) 7:00 (-22:80 to -17:70) 8:80 (-28:20 to -17:70) 8:80 (-28:20 to -11:00)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.10 (0.02 to 0.40) 0.10 (0.02 to 0.40) 0.19 (0.06 to 0.39) 0.28 (0.18 to 0.42) 0.28 (0.18 to 0.42) 0.15 (0.07 to 0.31)	-				
All-Cause Mortality Sex Women 2 Age group 4 < 60 60 − 64 2 70 − 74 4 50 − 80 50 50 50 60 − 60 70 − 74 50 50 50 60 − 60 50 50 50 60 − 60 50 50 50 50 50 50 50 50 50 50 50 50 50	1/115 9(345 1) 1/115 9(345 1) 1/115 9(345 7) 3/89 7) 5/108 1) 2/171 2) 2/171 2) 2/172 2) 2/2 /24 5) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 2/2 /	124 / 7013	120 (-25.80 to -16.50) 42 (-14.00 to 1.19) 29 (-25.10 to 6.55) 00 (-18.00 to 4.03) 1.30 (-20.30 to -2.36) 60 (-24.20 to -4.39) 4.20 (-28.90 to -11.950) 8.50 (-24.00 to -13.00) 7.00 (-22.80 to -11.00) 7.00 (-28.20 to -11.00) 7.00 (-28.20 to -11.00) 8.60 (-26.20 to -11.00) 8.60 (-26.20 to -11.00) 3.00 (-28.80 to -16.80)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.56 (0.20 to 1.23) 0.10 (0.02 to 0.40) 0.10 (0.02 to 0.40) 0.19 (0.09 to 0.39) 0.26 (0.18 to 0.39) 0.27 (0.18 to 0.31) 0.21 (0.16 to 0.28)					
All-Cause Mortality Sex Women a Age groups 60 – 64 a 50 – 66 a 50 – 66 a 50	1/115 9(345 1) 1/115 9(345 1) 1/115 9(345 7) 3/89 7) 5/108 1) 2/171 2) 2/171 2) 2/172 2) 2/2 /24 5) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 2/2 /	124 / 7013	1:20 (-25:80 to -16:50) 4:2 (-14:00 to 1.19) 20 (-25:10 to 6.35) (-18:00 to 4.33) 1:30 (-2030 to -2.28) 6:00 (-24:20 to -4.39) 4:20 (-28:90 to -19:50) 5:80 (-24:00 to -13:00) 7:00 (-22:80 to -11:00) 7:00 (-22:80 to -17:70) 8:80 (-28:20 to -17:70) 8:80 (-28:20 to -11:00)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.50 (0.20 to 1.23) 0.10 (0.02 to 0.40) 0.10 (0.02 to 0.40) 0.19 (0.06 to 0.39) 0.28 (0.18 to 0.42) 0.28 (0.18 to 0.42) 0.15 (0.07 to 0.31)					
All-Cause Mortality Sex Women	1/115 9(345 1) 1/115 9(345 1) 1/115 9(345 7) 3/89 7) 5/108 1) 2/171 2) 2/171 2) 2/172 2) 2/2 /24 5) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 5/2 /524 6) 2/2 /	124 / 7013	120 (-25.80 to -16.50) 42 (-14.00 to 1.19) 29 (-25.10 to 6.55) 00 (-18.00 to 4.03) 1.30 (-20.30 to -2.36) 60 (-24.20 to -4.39) 4.20 (-28.90 to -11.950) 8.50 (-24.00 to -13.00) 7.00 (-22.80 to -11.00) 7.00 (-28.20 to -11.00) 7.00 (-28.20 to -11.00) 8.60 (-26.20 to -11.00) 8.60 (-26.20 to -11.00) 3.00 (-28.80 to -16.80)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.56 (0.20 to 1.23) 0.10 (0.02 to 0.40) 0.10 (0.02 to 0.40) 0.19 (0.09 to 0.39) 0.26 (0.18 to 0.39) 0.27 (0.18 to 0.31) 0.21 (0.16 to 0.28)					
All-Cause Mortality Sex Women Sex Age group < 60 60 - 64 60 - 64 60 - 64 70 - 74 70 - 74 75 - 80 50 01 01 02 03 03 03 04 04 04 04 04 04 04 04 04 04 04 04 04	36 / 783 1 1 28 / 845 1 / 1 / 115 99 3 / 89 7 2 5 / 108 1 1 6 / 177 1 2 2 / 171 2 2 / 171 2 2 / 171 2 2 / 77 988 1 8 / 283 22 2 / 567 99 2 / 567 90 2 / 567 90 2 / 567 90 2 / 569 90 2 / 56	124 / 7013 - 1 992 / 8398 - 2 9/ 2812 - 4 8 / 723 - 5 14 / 1019 - 7 37 / 138 - 1 12 / 1487 - 1 12 / 1487 - 1 12 / 1487 - 1 13 / 138 - 1 15 / 2029	120 (-25.80 to -16.50) 42 (-14.00 to 1.19) 29 (-25.10 to 6.55) 00 (-18.00 to 4.03) 1.30 (-20.30 to -2.36) 60 (-24.20 to -4.39) 4.20 (-28.90 to -11.950) 8.50 (-24.00 to -13.00) 7.00 (-22.80 to -11.00) 7.00 (-28.20 to -11.00) 7.00 (-28.20 to -11.00) 8.60 (-26.20 to -11.00) 8.60 (-26.20 to -11.00) 3.00 (-28.80 to -16.80)	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.36 (0.11 to 1.15) 0.56 (0.20 to 1.23) 0.10 (0.02 to 0.40) 0.10 (0.02 to 0.40) 0.19 (0.09 to 0.39) 0.26 (0.18 to 0.39) 0.27 (0.18 to 0.31) 0.21 (0.16 to 0.28)					
Alf-Cave Montaliy Sec Women (= 10 Men (= 10 Aleg croup) < 60 - 64 (= 10 60 - 64 (= 10 60 - 64 (= 10 70 - 74 (= 10 70 - 74 (= 10 70 - 74 70 - 74 10 - 10 10 - 10 1	36 / 783 1 ' 28 / 845 1 ' 1 / 115 90 3 / 89 7' 5 / 108 1 ' 2 / 171 2' 2 / 175 2' 8 / 283 2' 8	124/7013 -1 1992/8398 -3 0/2812 -4 1/723 -5 1/723 -5 1/14/1019 -1 3/1138 -1 3/1138 -1 3/2/1487 -1 3/1138 -1 3/2/1487 -1 3/2/147 -1 3/2/147 -1 3/2/14/202 -1 -1 5/2/202 -1 -1 5/2/202 -1 -1 -2 5/2/202 -1 -1 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2	120 (2580 to -16.50) 422 (44.00 to 1.10) 20 (25.10 to 6.50) 0.1180 to 4.30 130 (23.00 to 2.30) 650 (24.20 to 4.30) 420 (28.00 to -15.00) 850 (24.00 to -15.00) 260 (24.20 to -11.00) 272 (38.70 to -17.70) 860 (28.20 to -17.00) 860 (28.20 to -17.00) 360 (23.20 to -16.80) 8.0 (24.00 to 6.30) 8.0 (24.00	0.19 (0.13 to 0.28) 0.23 (0.03 to 1.80) 0.30 (0.11 to 1.15) 0.30 (0.11 to 1.15) 0.30 (0.14 to 0.75) 0.31 (0.14 to 0.75) 0.31 (0.14 to 0.75) 0.22 (0.17 to 0.30) 0.22 (0.15 to 0.25) 0.22 (0.15 to 0.25) 0.21 (0.16 to 0.25) 0.25 (0.28 to 1.15) 0.55 (0.28 to 1.15)					
Alf-Gause Mortality Sec Woman () Woman () Man Man () Alegroup < 60 – 64 – 0 60 – 64 –	38 / 783 1 1 28 / 845 1 1 1 / 115 96 3 / 99 7 7 5 / 108 1 7 1 / 115 97 7 7 / 11 6 / 177 1 1 2 / 171 2 2 / 156 1 1 8 / 283 22 1 / 171 22 7 / 567 90 2 / 171 98 8 / 283 22 7 / 567 90 7 / 254 55 7 / 255	124/7013 -1 124/7013 -1 1723 4 1/723 4 1/723 4 1/138 -1 1/14/1019	120 (25 80 to -16 50) 42 (24 00 to 119) 22 (25 10 to 150) 20 (25 10 to 150) 83 (24 20 to 16 50) 84 (24 20 to -88) 85 (24 20 to -88) 85 (24 20 to -18 20) 85 (24 20 to -18 20) 22 (35 0 to -18 20) 23 (32 30 to -18 30) 30 (23 30 to -18	0.19 (0.13 to 2.29) 0.23 (0.16 1.20) 0.33 (0.116 1.10) 0.33 (0.116 1.10) 0.33 (0.116 1.10) 0.31 (0.146 0.27) 0.31 (0.146 0.27) 0.19 (0.06 0.30) 0.22 (0.15 to 3.37) 0.22 (0.15 to 4.27) 0.21 (0.16 to 4.27) 0.55 (0.28 (0.110) 0.55 (0.28					
Alf-Cause Mortality Sec Woman () Man () Ma	38 / 783 1 1 28 / 845 1 / 1 / 115 94 3 / 89 7 7 5 / 108 1 7 6 / 177 1 1 6 / 177 1 1 6 / 177 1 1 6 / 177 1 1 6 / 177 1 1 8 / 283 22 / 171 2 27 / 567 90 2 / 171 2 55 / 1506 2 9 / 120 1 1 17 / 783 0 1 / 14 / 845 92 1 / 1/15 4 1 / 1/15 4	124 / 7013 128 / 208 1728 12 1728 12 1728 12 1773 1338 121 147 177 1564 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197 197	1.20 (25.80 to -16.50) 4.2 (14.00 to 119) 22 (24.10 to 15.60) 20 (24.00 to 15.60) 20 (24.00 to 4.00) 1.13 (26.20 to -2.80) 4.02 (25.00 to -1.80) 20 (24.00 to -1.90) 20 (24.00 to -1.90) 20 (24.20 to -1.100) 3.03 (23.20 to -1.60) 3.03 (23.20 to -1.60) 3.03 (23.20 to -1.60) 3.03 (23.20 to -1.60) 2.00 (-15.70 to 4.20) 4.10 ((-17.70 to -1.60) 2.00 (-15.70 to 4.20) 4.10 ((-17.20 to -1.60)	0.19 (0.13 to 2.26) 0.22 (0.04 to 1.80) 0.30 (0.14 to 1.10) - 0.31 (0.14 to 2.07) - 0.10 (0.02 to 2.01) - 0.22 (0.17 to 0.27) - 0.22 (0.17 to 0.27) - 0.22 (0.15 to 0.28) - 0.22 (0.15 to 0.28) - 0.21 (0.15 to 0.28) - 0.24 (0.08 to 2.77) -					
Alf-Cause Morhally Set Woman	38 / 783 1 1 28 / 845 1 / 1 / 115 96 3 / 99 7 / 5 / 108 1 1 6 / 177 1 1 6 / 177 1 1 6 / 177 1 1 7 / 178 2 / 17 / 567 90 22 / 564 91 7 / 254 5 55 / 1508 2 / 9 / 120 1 1 17 / 783 60 14 / 845 92 1 / 185	124 / 7013 - 1 162 / 898 - 2) / 2812 - 4) / 2812 - 4) / 2812 - 4) / 2812 - 4 14 / 1019 - 7 35 / 37 / 1338 - 2 35 / 2029 - 1 35 / 2029 - 1 36 / 2029 - 1 36 / 2029 - 1 36 / 2029 - 1 37 / 5624 - 2 36 / 2029 - 1 36 / 2029 - 1 36 / 2029 - 1 37 / 5624 - 2 36 / 2029 - 1 36 / 2029 - 1 37 / 5624 - 2 36 / 2029 - 1 36 / 2029 - 1 37 / 5624 - 2 36 / 2029 - 1 37 / 5624 - 2 37 /	120 (25 80 to -16 50) 42 (24 00 to 119) 22 (25 10 to 150) 20 (25 10 to 150) 83 (24 20 to 16 50) 84 (24 20 to -88) 85 (24 20 to -88) 85 (24 20 to -18 20) 85 (24 20 to -18 20) 22 (35 0 to -18 20) 23 (32 30 to -18 30) 30 (23 30 to -18	0.19 (0.13 to 2.28) 0.23 (0.05 1.20) 0.53 (0.15 1.20) 0.53 (0.15 1.20) 0.53 (0.15 1.20) 0.31 (0.15 0.26) 0.31 (0.15 0.26) 0.32 (0.15 0.32) 0.22 (0.15 0.32) 0.22 (0.15 0.42) 0.22 (0.15 0.42) 0.55 (0.28 0.110) 0.21 (0.15 0.42) 0.55 (0.28 0.110) 0.24 (0.16 0.22) 0.54 (0.06 0.22) 0.42 (0.05 0.27) 0.42 (0.05 0.27) 0.42 (0.05 0.27) 0.42 (0.05 0.27) 0.44 (0.06 0.27) 0.44 (0					
Alf-Cause Morhally Sea Women	36 / 783 1 1 28 / 845 1 1 / / 115 00 3 / 69 7 7 5 / 108 1 1 2 / 171 22 / 77 108 1 1 2 / 171 22 / 77 167 01 2 / 178 22 / 554 6 1 55 / 1506 2 9 / 120 1 1 17 / 783 60 1 / 4 / 845 92 1 / 115 4 / 1 / 86 4 / 1 / 18 4 / 18	124 / 7013	120 (25 80 to -16 50) 42 (24 00 to 119) 22 (25 10 to 150) 20 (25 10 to 150) 20 (25 10 to 150) 85 (24 20 to -8 80) 45 (24 20 to -8 80) 85 (24 20 to -18 20) 85 (24 20 to -18 20) 20 (23 20 to -18 20) 20 (23 20 to -18 20) 20 (23 20 to -18 20) 20 (15 70 to -4 20) 20 (15 70 to -4 20) 20 (15 70 to -5 30) 20 (15 70	0.19 (0.13 to 2.26) 0.22 (0.04 to 1.80) 0.30 (0.14 to 1.10) - 0.31 (0.14 to 2.07) - 0.10 (0.02 to 2.01) - 0.22 (0.17 to 0.27) - 0.22 (0.17 to 0.27) - 0.22 (0.15 to 0.28) - 0.22 (0.15 to 0.28) - 0.21 (0.15 to 0.28) - 0.24 (0.08 to 2.77) -					
Alt-Cause Montally Set Women 1 Man 2 Man 2 Man 2 Man 2 Set 2 Solo 2 Solo 2 Solo 2 G1 1 Q2 2 Q3 2 Q4 2 Dibbets 2 Woman 4 Apg group 4 G5 2 Q1 1 Max 1	36 / 783 1 1 28 / 845 1 4 / / 115 00 3 / 69 7 7 / 5 / 108 1 1 2 / 171 22 / 77 / 68 1 1 2 / 171 22 / 77 / 68 1 1 8 / 27 / 567 0 2 / 57 / 607 0 2 / 57 / 67 0 2 / 172 1 14 / 845 22 / 178 4 / 1 / 150 4 / 1 / 170 1 / 1 / 170 1 / 1 / 170 1	124 / 7013	1.20 (22.50 to -16.50) 4.2 (14.00 to 119) 22 (23.10 to 150) 22 (23.10 to 150) 23 (23.10 to -23) 6.60 (24.20 to -1.60) 6.60 (24.20 to -1.60) 7.00 (22.00 t	0.19 (0.13 to 2.26) 0.22 (0.04 to 1.80) 0.23 (0.16 to 1.80)					

Figure 1. Association of Antivirals Use with Mortality and Organ Dysfunction. (**a**) Association between Nirmatrelvir-Ritonavir and Molnupiravir Use, All-Cause Mortality, and Major Organ Dysfunction Events in 17.704 Hospitalized Patients Infected with Omicron Variant of SARS-CoV-2; (**b**) Association between Nirmatrelvir-Ritonavir and Molnupiravir Use, All-Cause and Respiratory Mortality, Stratified by Age, Sex, SDI and Diabetes. Abbreviations: *IRD* incidence rate difference; *HR* hazard ratio; *SDI* social deprivation index. Weighted incidence rate differences comparing Nirmatrelvir-Ritonavir and Molnupiravir Users to non-users after inverse probability weighting was applied. Composite: Time to first circulatory shock, respiratory failure, coagulopathy, acute kidney injury and acute liver impairment. There were fewer composite events compared with total individual events, as participants were censored at first event of interest.

2.0 3.0

Q1 Q2 Q3 Q4 Diabet No

12 / 56

4/254

28 / 1508 3 / 120 343/263

1509 / 14390 122 / 1021 12.30 (-17.00 to -7.65)

-18.40 (-26.00 to -10.80 -11.10 (-16.80 to -5.42)

-13.40 (-16.10 to -10.70) -9.08 (-18.20 to 0.04) 0.19 (0.11 to 0.34) 0.20 (0.11 to 0.36)

0.12 (0.04 to 0.32)

0.17 (0.12 to 0.25) 0.26 (0.08 to 0.84)

0.65 (0.52 to 0.80) 0.62 (0.54 to 0.71) 0.63 (0.54 to 0.73) 0.64 (0.52 to 0.78) 0.64 (0.59 to 0.70) HR (95% C.L.) 1.00 (0.72 to 1.39) 1.40 (1.05 to 1.87) -1.15 (0.66 to 1.99) 1.25 (0.89 to 1.75) 1.13 (0.76 to 1.70) 1.21 (0.69 to 2.12) 1.23 (0.99 to 1.54) 0.74 (0.30 to 1.84) HR (95% C.I. 0.39 (0.10 to 1.63) -0.30 (0.04 to 2.24) 0.76 (0.23 to 2.47) 0.57 (0.14 to 2.38) 0.51 (0.07 to 3.78) . -0.49 (0.21 to 1.12) 1.94 (0.21 to 17.60) . HR (95% C.L) 0.84 (0.59 to 1.19) 0.66 (0.48 to 0.90) 2 1.29 (0.47 to 3.52) 0.61 (0.22 to 1.69) 0.28 (0.09 to 0.90) 0.60 (0.29 to 1.24) 1.07 (0.63 to 1.83) 0.72 (0.53 to 0.98) 0.77 (0.46 to 1.28) 0.52 (0.34 to 0.81) 0.81 (0.54 to 1.21) 1.15 (0.66 to 2.00) 0.77 (0.61 to 0.96) HR (95% C.I.) 1.08 (0.63 to 1.86) 0.98 (0.60 to 1.60) 1.32 (0.18 to 9.9 0.73 (0.09 to 5.6 0.00 (0.00 to 0.0 1.04 (0.31 to 3.4 1.39 (0.57 to 3.37) 1.01 (0.55 to 1.83) 1.02 (0.53 to 1.97) 0.81 (0.32 to 2.04) -0.99 (0.67 to 1.46) 1.35 (0.47 to 3.89) . -HR (95% C.I.) 0.63 (0.55 to 0.72) 0.52 (0.45 to 0.59) ÷ 25 / 115 20 / 89 26 / 108 27 / 177 50 / 171 1.70 (1.14 to 2.54) 0.72 (0.45 to 1.14) -0.72 (0.45 to 1.14) 0.64 (0.43 to 0.94) 0.35 (0.24 to 0.51) 0.64 (0.48 to 0.86) 0.52 (0.46 to 0.58) 1 0.90 to -21 SDI Q1 Q2 Q3 Q4 i 0.60 (0.48 to 0.76) 75/283 0.57 (0.49 to 0.67) 0.55 (0.47 to 0.65) 0.56 (0.45 to 0.70) 2309/ 2049/ 1152/ -17.40 (-22.70 to -12. -17.00 (-22.40 to -11. -20.20 (-28.70 to -11. 163/561 144/524 78/254 No Yes 425 / 1508 35 / 120 5758 / 14390 466 / 1021 0.57 (0.52 to 0.63) -16.50 (-19.60 to -13.30 -21.60 (-33.90 to -9.27)

÷

2

Figure 2. Association of Antivirals Use with Organ Dysfunction, Stratified by Age, Sex, SDI and Diabetes. (a) Association between Nirmatrelvir-Ritonavir and Major Organ Dysfunction Events in Hospitalized Patients Infected with Omicron Variant of SARS-CoV-2; (b) Association between Molnupiravir and Major Organ Dysfunction Events in Hospitalized Patients Infected with Omicron Variant of SARS-CoV-2. Abbreviations: IRD incidence rate difference; HR hazard ratio; SDI social deprivation index. Weighted incidence rate differences comparing Nirmatrelvir-Ritonavir and Molnupiravir Users to non-users after inverse probability weighting was applied. Composite: Time to first circulatory shock, respiratory failure, coagulopathy, acute kidney injury and acute liver impairment. There were fewer composite events compared with total individual events, as participants were censored at first event of interest.

24/133

109/62 6/45

No Yes

714/2029

2309 / 5624 2049 / 5121 1152 / 2637

5758 / 14390 466 / 1021

(-23.40 to -6.66

-24.20 (-31.70 to -16.60) -18.70 (-25.40 to -12.00) -28.00 (-40.80 to -15.10)

-20.10 (-24.30 to -15.80) -27.60 (-44.10 to -11.10)

i

2.0 3.0 5.0

0.45 (0.30 to 0.68

0.28 (0.19 to 0.41) 0.45 (0.34 to 0.59) 0.25 (0.13 to 0.46)

0.38 (0.32 to 0.46)

⁽a) (b) Com Cor Composi Sex Women Men Age group < 60 60 - 64 65 - 69 70 - 74 75 - 79 Sex Wome Men Age gro < 60 66 / 333 87 / 332 0.41 (0.33 to 0.53) 273 293 -12.50 (-17.30 to -7.74 0.69 (0.61 to 0.79) 0.58 (0.51 to 0.65) -20.30 (-26.30 to -14.30 -23.20 (-30.30 to -16.20 32 / 115 27 / 89 36 / 108 36 / 177 63 / 171 372 / 968 417 / 2812 256 / 723 409 / 1019 576 / 1338 722 / 1487 8.79 (1.89 to 15.70) -5.67 (-20.00 to 8.61) -7.02 (-17.90 to 3.86) -21.20 (-29.90 to -12. 1.88 (1.31 to 2.68) 0.81 (0.55 to 1.21) 0.77 (0.55 to 1.08) 0.41 (0.29 to 0.57) 9/65 5/49 8/48 17.50 (-35.10 to 0.11) 19.60 (-32.70 to -6.60 60-64 65-69 70-74 0.27 (0.11 to 0.65) 0.36 (0.18 to 0.73) 22/98 16/68 93/337 >= 8 SDI Q1 Q2 Q3 Q4 >= 8 SDI Q1 Q2 Q3 Q4 Diabe No Yes 31/132 38/195 71/263 13/75 i 91 / 283 198 / 567 181 / 524 96 / 254 0.51 (0.36 to 0.73) 0.35 (0.26 to 0.48) 0.52 (0.41 to 0.66) 0.30 (0.17 to 0.51) 2558 / 5624 2272 / 5121 -25.80 (-34.30 to -17.30) -19.10 (-26.70 to -11.60) -29.40 (-43.40 to -15.30) 2558 / 5624 2272 / 5121 1239 / 2637 -16.60 (-22.70 to -10.60 -19.30 (-28.80 to -9.75) Diabe No Yes 0.45 (0.38 to 0.53) 145/620 8/45 526 / 1508 40 / 120 6362 / 1439 512 / 1021 -21.00 (-25.70 to -16.30) -31.10 (-49.80 to -12.30) 6362 / 14390 -16.50 (-20.10 to -12.90) -24.60 (-38.40 to -10.90) No. of Events / No. at ris No. of Events / No. at risk Weighted (95% C.I.) Weighted I (95% C.L) HR (95% C.I.) Acute kik Sex Women Men Age group 60 – 64 65 – 69 70 – 74 75 – 79 > = 80 SDI Q1 Q2 Q2 Q3 Q4 Diabetes No Yes Acute kin Sex -0.65 (-2.06 to 0.77) 0.67 (-0.89 to 2.23) Women Men Age group < 60 60 - 64 65 - 69 70 - 74 75 - 79 0.00 (-1.11 to 1.11) 0.88 (-0.21 to 1.97) 0.69 (0.37 to 1.30) 1.37 (0.84 to 2.23) 10 / 333 17 / 332 331 / 7013 345 / 8398 41 / 783 53 / 845 331/7013 . 9 (-0.74 to 3.88) 9 (-4.31 to 2.33 9 (-2.13 to 3.92) 5 (-2.39 to 2.10 4 (-3.35 to 1.28 3/65 0/49 2/48 6/98 1/68 51/2812 29/723 46/1019 6/115 2/89 7/108 8/177 7/171 1.63 (-1.16 to 4.43) -1.75 (-5.70 to 2.21) 0.19 (-3.45 to 3.83) 51 / 2812 29 / 723 001 ٠ SDI Q1 Q2 Q3 Q4 Diabet No Yes 4 / 132 9 / 195 13 / 263 1 / 75 0.71 (0.26 to 1.93) 1.06 (0.55 to 2.06) 1.30 (0.74 to 2.29) 0.36 (0.05 to 2.60) 0.34 (-1.45 to 2.13) 0.66 (-0.76 to 2.07) 0.30 (-1.01 to 1.61) 0.48 (-1.43 to 2.39) 84 / 2029 271 / 5624 215 / 5121 106 / 2637 -0.61 (-2.84 to 1.63) 0.13 (-1.92 to 2.18) 0.56 (-1.18 to 2.30) -1.14 (-3.59 to 1.31) 15 / 283 38 / 567 27 / 524 14 / 254 84 / 2029 271 / 5624 215 / 5121 106 / 2637 ţ 1.01 (0.68 to 1.51) 0.91 (0.22 to 3.78) 25/620 2/45 0.03 (-1.06 to 1.11) -0.22 (-4.62 to 4.18) 89 / 1508 5 / 120 619 / 143 57 / 1021 0.55 (-0.26 to 1.36) -0.72 (-3.45 to 2.01) 3.0 No. of Events / No. at risk Nirmatrelvir-ritonavir Control No. of Events / No. at risk Weighted I (95% C.I.) Weighted I (95% C.J.) HR (95% C.I.) Molnus wir Control Acute live Sex Women Men Age group < 60 60 - 64 65 - 60 70 - 74 75 - 79 >= 80 SDI Q1 Q2 Q3 Q3 Q4 Acute Im Sex Women Mon Age group < 60 60 - 64 65 - 69 70 - 74 75 - 79 -1.23 (0.39 to 3.94) 0.29 (0.04 to 2.12) 4/333 46 / 7013 0.11 (-0.65 to 0.86) -0.35 (-0.94 to 0.25 2/783 46 / 7013 -0.61 (-0.92 to 2.13) -0.41 (-2.30 to 1.49 -0.22 (-1.01 to 0.58 -0.98 (-2.46 to 0.49 0.16 (-1.70 to 2.02) 5.69 (0.72 to 4 0.00 (0.00 to 0 0.00 (0.00 to 0 0.00 (0.00 to 0 1.29 (0.15 to 1 0.87 (0.27 to 2 1/65 0/49 0/48 0/98 1/68 3/337 Q1 Q2 Q3 Q4 0.42 (0.05 to 3.53) 0.74 (0.10 to 5.37) 1.32 (0.40 to 4.36) 0.00 (0.00 to 0.00) 1/132 1/195 3/263 0/75 22 / 2029 41 / 5624 36 / 5121 21 / 2637 -0.49 (-1.80 to 0.81) -0.09 (-0.82 to 0.65) 0.13 (-0.68 to 0.95) -0.42 (-1.43 to 0.59) 1/283 3/567 2/524 1/254 -0.39 (-1.08 to 0.30 No Yes No Yes -0.11 (-0.63 to 0.40 0.77 (0.30 to 1.98) 0.00 (0.00 to 0.00) 5/620 0/45 116 / 1439 4 / 1021 6 / 1508 1 / 120 -0.20 (-0.46 to 0.07 0.20 (-0.77 to 1.16) No. of Even No. of E Weighted IRD/ 1000 pr (95% C.I.) IRD/ 1000 p HR (95% C.I.) Weighted (95% C.L) Circu Circi Sex Women Age grou < 60 60 - 64 65 - 69 70 - 74 75 - 79 >= 80 SDI Q1 Q2 Q3 Q4 0.37 (0.17 to 0.83) -0.42 (-1.49 to 0.65) -1.32 (-2.52 to -0.11) 6 / 333 12 / 332 -1.51 (-2.87 to -0.15) -1.81 (-3.57 to -0.05) 34 / 783 43 / 845 Men Age gros < 60 2.25 (0.70 to 7.18) 0.39 (0.05 to 2.87) 0.00 (0.00 to 0.00) 0.39 (0.12 to 1.23) 0.36 (0.09 to 1.46) 0.46 (0.24 to 0.89) 4 / 115 4 / 89 3 / 108 8 / 177 15 / 171 43 / 968 0.38 (-1.69 to 2.46) -1.47 (-6.05 to 3.12) -3.51 (-6.70 to -0.32) -1.51 (-4.14 to 1.11) 3/65 1/49 0/48 3/98 2/68 9/337 1.29 (-1.68 to 4.25) -1.60 (-6.84 to 3.65) -4.59 (-8.36 to -0.81) -2.36 (-5.80 to 1.08) -2.57 (-6.60 to 1.45) < 60 60 - 64 65 - 69 70 - 74 75 - 79 10/2812 52/723 95/1019 101/1338 123/1487 52 / 723 --0.87 (-2.98 to 1.23) -1.72 (-3.06 to -0.37) -0.59 (-2.00 to 0.83) 0.36 (-1.59 to 2.32) 7 / 132 3 / 195 8 / 263 0 / 75 -0.71 (-3.65 to 2.23) -2.47 (-4.45 to -0.50) -1.39 (-3.17 to 0.39) -2.07 (-4.37 to 0.22) 16/283 21/567 26/524 14/254 138/2029 372/5624 306/5121 118/2637 0.79 (0.37 to 1.69 Q1 Q2 Q3 -0.23 (0.08 to 0.73) 0.52 (0.28 to 1.05) 0.00 (0.00 to 0.00) 372 / 5624 306 / 5121 118 / 2637 No Yes No 17/620 74 / 150 3 / 120 851 / 14390 83 / 1021 -1.57 (-2.72 to -0.43) -2.81 (-7.41 to 1.80) 0.46 (0.29 to 0.75) 85 2.0 No. of Ev No. at risi Weighte (95% CJ Nim avir Control Weightea (95% C.I.) HR (95% C.J.) Control Coa Sex Coa 15 / 783 18 / 845 5/333 9/332).93 to 0.88) .64 to 1.56) 0.96 (0.39 to 2.38) 1.53 (0.78 to 3.02) Women Men 4ge group < 60 60 - 64 65 - 69 70 - 74 75 - 79 >= 80 SDI Q1 Q2 Q3 Q4 5 Men Age group < 60 60 - 64 65 - 69 70 - 74 75 - 79 0.10 (-0.92 to 1.12) -0.20 (-2.25 to 1.85 -1.01 (-2.25 to 0.22 1/115 1/89 0/108 3/177 5/171 18 / 2812 12 / 723 21 / 1019 22 / 1338 31 / 1487 1/65 0/49 0/48 4/98 1/68 8/337 . 0.00 (0.00 to 0.00) 0.00 (0.00 to 0.00) 3.18 (1.07 to 9.43) 0.76 (0.10 to 5.61) 1.19 (0.58 to 2.43) 01 02 03 6/283 12/567 10/524 5/254 3/132 4/195 5/263 2/75 1.70 (0.51 to 5.65) 1.06 (0.39 to 2.87) 1.24 (0.50 to 3.07) 1.36 (0.33 to 5.63) 27 / 2029 112 / 562 89 / 5121 58 / 2637 0.29 (-0.79 to 1.37 0.01 (-0.81 to 0.82 0.02 (-0.78 to 0.82 -0.22 (-1.47 to 1.0 0.05 (-1.30 to 1.41) 0.18 (-0.90 to 1.26) 0.35 (-2.02 to 2.72) 112 / 5624 89 / 5121 58 / 2637 No Yes No Yes 12/620 2/45 --0.01 (-0.49 to 0.47) 0.43 (-1.66 to 2.52) 0.15 (-0.57 to 0.86) 1.20 (-2.45 to 4.84) 1.18 (0.66 to 2.12) 2.18 (0.51 to 9.29) 259 / 14390 27 / 1021 2.0 0.0 No. of Events / No. at risk No. of Events / No. at risk Nirmatrely avir Control Weighted (95% C.L) 1978 HR (95% C.L.) Molr wir Control Respirato Sex Women Man Age group < 60 60 – 64 65 – 69 70 – 74 75 – 79 >= 80 SDI Q1 Q2 Q2 Q3 Q4 -12.70 (-16.80 to -8.48) 0.36 (0.27 to 0.48) 50 / 333 65 / 332 2628 / 7013 3596 / 8398 -18.50 (-23.80 to -13.20) -22.90 (-29.20 to -16.60) 222/783 2628 / 7013 0.92 (0.44 to 1.94) 0.25 (0.09 to 0.67) 0.32 (0.14 to 0.73) 0.31 (0.18 to 0.54) 0.37 (0.21 to 0.67) 0.35 (0.28 to 0.44) 358 / 2812 218 / 723 359 / 1019 512 / 1338 639 / 1487 5.72 (-0.18 to 11.60 0.46 (-6.08 to 5.16 -14.20 (-29.50 to 1.17) -17.30 (-28.70 to -5.79 -19.50 (-29.80 to -9.25) -21.40 (-34.80 to -8.00 -6.20 (-18.20 to 5.80 -9.55 (-18.70 to -0.4) -19.30 (-27.00 to -11 13 / 98 12 / 68 73 / 337

	Number of mortalities			
	Nirmatrelvir-ritonavir	Molnupiravir	Control	P value
Circulatory shock	38 (60.3)	378 (54.4)	7 (63.6)	0.561
Respiratory failure	226 (54.7)	2233 (42.0)	50 (48.5)	< 0.001
Acute kidney injury	81 (100.0)	518 (98.7)	21 (100.0)	0.503
Coagulopathy	19 (67.9)	190 (91.3)	10 (83.3)	0.001
Acute liver impairment	5 (83.3)	88 (100.0)	4 (100.0)	< 0.001
Organ dysfunction composite	293 (57.6)	2577 (44.0)	79 (57.7)	< 0.001

Table 3. Number of mortalities in the nirmatrelvir-ritonavir, molnupiravir and control groups, stratified by organ dysfunction.

.....

more definitively determine the role of antiviral therapy in high-risk COVID-19 adults for primary prevention of all-cause mortality and sepsis.

Data availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 8 September 2022; Accepted: 11 May 2023 Published online: 15 May 2023

References

- 1. Organization. WH. Tracking SARS-CoV-2 variants (2022) [Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants.
- 2. Organization. WH. WHO Coronavirus (COVID-19) Dashboard (2020) [Available from: https://covid19.who.int/?gclid=CjwKC AjwkYGVBhArEiwA4sZLuNN_QKvxWQaLdOHcSneX_tD8dY7l60_eesUPV0jSIG85YmDh6AKMNxoC_fAQAvD_BwE.
- 3. Del Rio, C., Omer, S. B. & Malani, P. N. Winter of Omicron-The evolving COVID-19 pandemic. JAMA 327(4), 319-320 (2022).
- 4. Young, B., Fong, S. –W., Chang, Z. W., Tan, K. S., Rouers, A., Goh, Y. S., *et al.* Comparison of the clinical features, viral shedding and immune response in vaccine breakthrough infection by the Omicron and Delta variants (2022).
- 5. Sun, Y.-J. et al. Clinical features of fatalities in patients with COVID-19. Disaster Med. Public Health Prep. 15(2), e9-e11 (2021).
- 6. Ranard, L. S. et al. Approach to acute cardiovascular complications in COVID-19 infection. Circ. Heart Failure 13(7), e007220 (2020).
- 7. La Porta, E. et al. The role of kidney dysfunction in COVID-19 and the influence of age. Sci. Rep. 12(1), 8650 (2022).
- 8. Tian, D., Sun, Y., Xu, H. & Ye, Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J. Med. Virol. 94(6), 2376–2383 (2022).
- Baig, A. M. & Sanders, E. C. Potential neuroinvasive pathways of SARS-CoV-2: Deciphering the spectrum of neurological deficit seen in coronavirus disease-2019 (COVID-19). J. Med. Virol. 92(10), 1845–1857 (2020).
- Sohn, K. M., Lee, S. –G., Kim, H. J., Cheon, S., Jeong, H., Lee, J., et al. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J. Korean Med. Sci. 35(38) (2020)
- 11. JaykBernal, A. et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N. Engl. J. Med. 386(6), 509–520 (2022).
- 12. Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8), 801-810 (2016).
- Karakike, E. et al. Coronavirus disease 2019 as cause of viral sepsis: A systematic review and meta-analysis. Crit. Care Med. 49(12), 2042 (2021).
- 14. Gu, X., Zhou, F., Wang, Y, Fan, G., Cao, B. Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. *Eur. Respir. Rev.* 29(157) (2020).
- Lin, G.-L., McGinley, J. P., Drysdale, S. B. & Pollard, A. J. Epidemiology and immune pathogenesis of viral sepsis. Front. Immunol. 9, 2147 (2018).
- Nyberg, T. *et al.* Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: A cohort study. *Lancet* 399(10332), 1303–1312 (2022).
- Saravolatz, L. D., Depcinski, S. & Sharma, M. Molnupiravir and Nirmatrelvir-Ritonavir: Oral coronavirus disease 2019 antiviral drugs. Clin. Infect. Dis. 76(1), 165–171 (2023).
- Centre for health Protection TGoHKSAR. *Statistics on 5th Wave of COVID-19 (from 31 Dec 2021 up till 5 Mar 2022 00:00).* (2022).
 McMenamin, M. E. *et al.* Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in
- Hong Kong: A population-based observational study. *Lancet Infect. Dis.* 22(10), 1435–1443 (2022).
 20. Mesfin, Y. *et al.* Epidemiology of infections with SARS-CoV-2 Omicron BA 2 variant in Hong Kong, January–March 2022. *medRxiv*
- 2022.04, 07.22273595 (2022).
- 21. Wai, A. K. *et al.* Changes in emergency department visits, diagnostic groups, and 28-day mortality associated with the COVID-19 pandemic: A territory-wide, retrospective, cohort study. *Ann. Emerg. Med.* **79**(2), 148–157 (2022).
- 22. Ye, Y. et al. Validation of diagnostic coding for interstitial lung diseases in an electronic health record system in Hong Kong. Pharmacoepidemiol. Drug Saf. 31(5), 519–523 (2022).
- Rhee, C. et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009–2014. JAMA 318(13), 1241–1249 (2017).
- Infection. HATFoCMo. Interim Recommendation on Clinical Management of Adult Cases with Coronavirus Disease 2019 (COVID-19) (2022).
- 25. Prevention. CfDCa. Hospital toolkit for adult sepsis surveillance. 2018 June 10 (2020).
- Liu, Y. Z. et al. A surveillance method to identify patients with sepsis from electronic health records in Hong Kong: A single centre retrospective study. BMC Infect. Dis. 20, 1–9 (2020).
- Wong, C.-M. et al. The effects of air pollution on mortality in socially deprived urban areas in Hong Kong, China. Environ. Health Perspect. 116(9), 1189–1194 (2008).

- Wong, C. H. A., Lam, T. & Bacon-Shone, J. Estimation of Variations in Health Care Needs Between Small Areas in HK Using Routine Statistics on Morbidity, Mortality and Socioeconomic and Demographic Characteristics of the Population (Health, Welfare and Food Bureau, 1999).
- 29. Allaire, J. RStudio: Integrated development environment for R. Boston MA 770(394), 165-171 (2012).
- 30. Kuhn, M., Wickham, H. Tidymodels: A collection of packages for modeling and machine learning using tidyverse principles. *Boston MA USA* (2020).
- 31. Therneau, T. A package for survival analysis in S. R package version 2(7) (2015).
- 32. Nakazawa, M. Functions for medical statistics book with some demographic data. 2019 (2013).
- 33. Greifer, N., Greifer, M. N. Package 'WeightIt'. CRAN (2019).
- 34. Gasparini, A. comorbidity: An R package for computing comorbidity scores. J. Open Source Softw. 3(23), 648 (2018).
- Johnson, M. G. et al. Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: A randomized, placebo-controlled trial. Ann. Intern. Med. 175(8), 1126–1134 (2022).
- Radcliffe, C., Palacios, C. F., Azar, M. M., Cohen, E. & Malinis, M. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the Omicron surge. Am. J. Transplant. 22(10), 2458–2463 (2022).
- 37. Hammond, J. et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N. Engl. J. Med. 386(15), 1397-1408 (2022).
- Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395(10229), 1054–1062 (2020).
- 39. Hikmet, F. et al. The protein expression profile of ACE2 in human tissues. Mol. Syst. Biol. 16(7), e9610 (2020).
- Conti, P. et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J. Biol. Regul. Homeost Agents 34(2), 327–331 (2020).
- Organization WH. Vaccines against influenza WHO position paper—November 2012. Wkly. Epidemiol. Rec. Relevé Épidémiol. Hebd. 87(47), 461–476 (2012).
- 42. Ortiz, J. R. et al. The burden of influenza-associated critical illness hospitalizations. Crit. Care Med. 42(11), 2325 (2014).
- Reed, C. et al. Complications among adults hospitalized with influenza: a comparison of seasonal influenza and the 2009 H1N1 pandemic. Clin. Infect. Dis. 59(2), 166–174 (2014).
- 44. Gentile, I. *et al.* Nirmatrelvir/Ritonavir and Molnupiravir in the treatment of mild/moderate COVID-19: Results of a real-life study. *Vaccines* **10**(10), 1731 (2022).
- 45. Wong, C. K. et al. Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA. 2 wave: A retrospective cohort study. Lancet Infect. Dis. 22(12), 1681–1693 (2022).
- 46. Wong, C. K. et al. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet 400(10359), 1213–1222 (2022).
- 47. Wai, A.K.-C. *et al.* Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19. *Lancet Reg. Health-West. Pac.* **30**, 100602 (2023).
- 48. Centre for Health Protection H. Archive of Statistics on 5th Wave of COVID-19 Hong Kong (2022) [Available from: https://www.coronavirus.gov.hk/eng/5th-wave-statistics.html.

Author contributions

A.W. and T.L. contributed to conception and design of the study. T.L., S.C., E.Y., L.L. and O.T. performed the study. S.C., E.Y. and L.L. carried out the data analysis. A.W., T.L., S.C., C.C., E.Y., L.L., J.H., K.S., O.T., M.L., S.L., T.Y., C.T., M.W., E.W. and T.R. contributed to the revision, read and approved the submitted version of the manuscript.

Funding

This study was supported by the Center for Health Systems and Policy Research which is founded with support from The Tung's Foundation, and in part by AIR@InnoHK of the Innovation and Technology Commission.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/ 10.1038/s41598-023-35068-w.

Correspondence and requests for materials should be addressed to T.H.R.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023